A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.
PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
18
Participants
Timeline
Start Date
November 15, 2025
Primary Completion Date
May 31, 2026
Study Completion Date
November 30, 2027
Conditions
Osteoarthritis, Knee
Interventions
GENETIC
ICM-203
Intra-articular injection
All Listed Sponsors
lead
ICM Co. Ltd.
INDUSTRY
NCT05454566 - A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis. | Biotech Hunter | Biotech Hunter